16P Camrelizumab monotherapy or plus apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A single-arm, open-label, multicenter, phase II study

Zhao, Mengnan; Liu, X.; Yuan, C.; Wei, Zheng; Zhang, D.; Long, Q.; Li, J.; Han, Tianci; Li, H.; Li, X.; Shi, Shuping

doi:10.1016/j.annonc.2022.02.025

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TRAEs of grade 3 or 4 were elevated AST/ALT (6.25%) and pituitary inflammation (6.25%), and no treatment-related deaths were reported. 19 This combination therapy of camrelizumab with apatinib has a relatively high ORR, and we need more prospective studies to demonstrate the feasibility of this therapy. In a study conducted by Qian et al ., in 21 patients diagnosed with stage III/IV PSC analyzed, 14 patients received a combination of ICIs with anlotinib, and 3 patients received single-agent immunotherapy.…”

Section: Immunotherapy For Pscmentioning

confidence: 99%

Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers

Ding,

Peng,

2024

Ther Adv Med Oncol

View full text Add to dashboard Cite

Pulmonary sarcomatoid carcinoma (PSC), a rare subtype of non-small cell lung cancer, is highly malignant and has a poor prognosis. Treatments for PSC are presently limited. Traditional treatments provide fewer benefits to PSC patients and are associated with early recurrence and metastasis. Surgical intervention is the preferred option for early-stage PSC patients, whereas chemotherapy, radiotherapy, immunotherapy, and other targeted therapies are recommended for advanced PSC patients. Targeted therapy is only effective in a small number of PSC patients. The initial efficacy of immune checkpoint inhibitors has been acceptable in patients with advanced PSC; therefore, much attention on related biomarkers has been sought. This article aimed to review the research progress of PSC immunotherapy and related diagnostic and prognostic biomarkers in recent years.

show abstract

Section: Immunotherapy For Pscmentioning

confidence: 99%

Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers

Ding,

Peng,

2024

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

“…136 Toripalimab was effective in treating advanced UC patients with PD-L1-positive TMB-H. 137 Camrelizumab monotherapy showed beneficial antitumor activity in patients with PD-L1-positive pulmonary sarcomatoid carcinoma. 138 Tislelizumab was used to treat adult patients with unresectable or metastatic MSI-H/dMMR in advanced solid tumors. 139 4.1.2 Anti-PD-L1 monotherapy…”

Section: Anti-pd-1 Monotherapymentioning

confidence: 99%

“… 137 Camrelizumab monotherapy showed beneficial antitumor activity in patients with PD‐L1‐positive pulmonary sarcomatoid carcinoma. 138 Tislelizumab was used to treat adult patients with unresectable or metastatic MSI‐H/dMMR in advanced solid tumors. 139 …”

Section: Treatment Strategies For Hot and Cold Tumorsmentioning

confidence: 99%

Hot and cold tumors: Immunological features and the therapeutic strategies

Wang,

Geng,

Liu

et al. 2023

MedComm

View full text Add to dashboard Cite

The “hotness” or “coldness” of the tumors are determined by the information of the cancer cells themselves, tumor immune characteristics, tumor microenvironment, and signaling mechanisms, which are key factors affecting cancer patients’ clinical efficacy. The switch mechanism of “hotness” and “coldness” and its corresponding pathological characteristics and treatment strategies are the frontier and hot spot of tumor treatment. How to distinguish the “hotness” or “coldness” effectively and clarify the causes, microenvironment state, and characteristics are very important for the tumor response and efficacy treatments. Starting from the concept of hot and cold tumor, this review systematically summarized the molecular characteristics, influencing factors, and therapeutic strategies of “hot and cold tumors,” and analyzed the immunophenotypes, the tumor microenvironment, the signaling pathways, and the molecular markers that contribute to “hot and cold tumors” in details. Different therapeutic strategies for “cold and hot tumors” based on clinical efficacy were analyzed with drug targets and proteins for “cold and hot tumors.” Furthermore, this review combines the therapeutic strategies of different “hot and cold tumors” with traditional medicine and modern medicine, to provide a basis and guidance for clinical decision‐making of cancer treatment.

show abstract

16P Camrelizumab monotherapy or plus apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A single-arm, open-label, multicenter, phase II study

Cited by 2 publications

References 0 publications

Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers

Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers

Hot and cold tumors: Immunological features and the therapeutic strategies

Contact Info

Product

Resources

About